Cited by 193Cytokine Signaling Pathways and InteractionsHead and Neck Cancer StudiesProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 148 of the 159 references it cites were found in a registry or an index.

The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations

Open access

Geiger, Jessica L., Grandis, Jennifer R., Bauman, Julie E.·2016·Oral Oncology

DOI 10.1016/j.oraloncology.2015.11.022PMC PMC5590227

Open this paper in CoChat — free account

Abstract

Proteins of the signal transducer and activator of transcription (STAT) family mediate cellular responses to cytokines and growth factors. Aberrant regulation of the STAT3 oncogene contributes to tumor formation and progression in many cancers, including head and neck squamous cell carcinoma (HNSCC), where hyperactivation of STAT3 is implicated in both treatment resistance and immune escape. There are no oncogenic gain-of-function mutations in HNSCC. Rather, aberrant STAT3 signaling is primarily driven by upstream growth factor receptors, such as Janus kinase (JAK) and epidermal growth factor receptor (EGFR). Moreover, genomic silencing of select protein tyrosine phosphatase receptors (PTPRs), tumor suppressors that dephosphorylate STAT3, may lead to prolonged phosphorylation and activation of STAT3. This review will summarize current knowledge of the STAT3 pathway and its contribution to HNSCC growth, survival, and resistance to standard therapies, and discuss STAT3-targeting agents in various phases of clinical development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.oraloncology.2015.11.022

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Cancer statistics, 2014
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T. A., Chang, J. C. S., Markman, M. M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
High Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer
Brocken, P., van der Heijden, E. H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus‐Oei, L. (2013) · Respiration · doi:10.1159/000347096 · Cited by 4,011
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M. E., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,711
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 1×
“IL-6 activates the JAK1 and 2 pathway through signal transduction, which leads to the activation of STAT3 by phosphorylation [75], thereby making the IL-6 receptor a target for drug development.”
Background
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Self-citation
Curcumin: From ancient medicine to current clinical trials
Hatcher, H., Planalp, R. P., Cho, J., Torti, F. M., & Torti, S. V. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7452-4 · Cited by 1,883
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
STATs in oncogenesis
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
Chaturvedi, A. K., Engels, E. A., Anderson, W. F., & Gillison, M. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1713 · Cited by 1,568
Colorectal cancer
Cunningham, D., Atkin, W. S., Lenz, H., Lynch, H. T., Minsky, B. D., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,447
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Smolen, J. S., Beaulieu, A. D., Rubbert‐Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., WOODWORTH, T. G., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,407
Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research.
Jurenka, J. S. (2009) · PubMed · Cited by 1,212
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L. G., Shain, K. H., Zhang, S., Bhattacharya, R., Gabrilovich, D. I., Heller, R. F., Coppola, D., et al. (2003) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,182
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Sheng, W., Zhang, S., Pilon‐Thomas, S., Niu, G., Kay, H. D., Mulé, J. J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,026
Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.
Grandis, J. R., & Tweardy, D. J. (1993) · PubMed · Cited by 851
Self-citation
Three-dimensional structure of the Stat3β homodimer bound to DNA
Becker, S., Groner, B., & Müller, C. W. (1998) · Nature · doi:10.1038/28101 · Cited by 802
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Xiong, L., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 651
Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Stat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
Grandis, J. R., Drenning, S. D., Zeng, Q., Watkins, S. C., Melhem, M. F., Endo, S., Johnson, D. E., Huang, L., He, Y., & Kim, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4227 · Cited by 588
Self-citation
Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
Chung, C. H., Ely, K., McGavran, L., Varella‐Garcia, M., Parker, J. S., Parker, N. B., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2587 · Cited by 570
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D. C., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B. E., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 547
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A. M., Buettner, R., Proia, D. A., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 529
Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells
Bharti, A. C., Donato, N. J., & Aggarwal, B. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3863 · Cited by 511
Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study
Illei, G. G., Shirota, Y., Yarboro, C. H., Daruwalla, J., Tackey, E., Takada, K., Fleisher, T. A., Balow, J. E., & Lipsky, P. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27221 · Cited by 509
Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.
Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507
Self-citation
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Inside the human cancer tyrosine phosphatome
Julien, S. G., Dubé, N., Hardy, S., & Tremblay, M. L. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2980 · Cited by 498
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Pardanani, A. D., Harrison, C. N., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D. W., Masszi, T., Mishchenko, E., Jourdan, É., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 497
Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1
Lee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. (2004) · Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 488
Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation
Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z. J., Haura, E. B., Laudano, A., Sebti, S. M., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 455
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 452
Targeting STAT3 in cancer: how successful are we?
Yue, P.-B., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 425
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 410
Self-citation
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A. D., Gotlib, J. R., Jamieson, C. H. M., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J. S., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 397
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo
Iwamaru, A., Szymański, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K. R., Conrad, C., Madden, T. L., Sawaya, R. A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210031 · Cited by 379
Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
Masuda, M., Suzui, M., Yasumatu, R., Nakashima, T., Kuratomi, Y., Azuma, K., Tomita, K., Komiyama, S., & Weinstein, I. B. (2002) · PubMed · Cited by 376
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
Garcia, R., Yu, C., Hudnall, A. M., Catlett, R., Nelson, K. L., Smithgall, T. E., Fujita, D. J., Ethier, S. P., & Jove, R. (1997) · PubMed · Cited by 369
Activation and Association of Stat3 with Src in v-Src-Transformed Cell Lines
Cao, X., Tay, A., Guy, G. R., & Tan, Y. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1595 · Cited by 359
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis
Chan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21032 · Cited by 355
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340
Self-citation
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
Papp, K. A., Menter, A., Abe, M., Elewski, B. E., Feldman, S. R., Gottlieb, A. B., Langley, R. G. B., Luger, T. A., Thaçi, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 326
Antioxidants and cancer, part 3: quercetin.
Lamson, D. W., & Brignall, M. S. (2000) · PubMed · Cited by 320
Curcumin Suppresses Janus Kinase-STAT Inflammatory Signaling through Activation of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 in Brain Microglia
Kim, H. Y., Park, E. J., Joe, E.-H., & Jou, I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6072 · Cited by 314
First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Self-citation
Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells
Shin, D., Kim, H.-N., Shin, K. D., Yoon, Y. J., Kim, S., Han, D. C., & Kwon, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2575 · Cited by 309
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 298
Curcumin Inhibits Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through Janus Kinase-STAT Pathway in T Lymphocytes
Natarajan, C., & Bright, J. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6506 · Cited by 290
Tanshinones: Sources, Pharmacokinetics and Anti-Cancer Activities
Zhang, Y., Jiang, P., Ye, M., Kim, S., Jiang, C., & Lü, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131013621 · Cited by 263
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M. P., Haura, E. B., Sebti, S. M., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 258
Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators
Lo, H., Cao, X., Zhu, H., & Ali‐Osman, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4923 · Cited by 257
Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas
Brantley, E. C., & Benveniste, E. N. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2180 · Cited by 239
Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor
Miyoshi, K., Takaishi, M., Nakajima, K., Ikeda, M., Kanda, T., Tarutani, M., Iiyama, T., Asao, N., DiGiovanni, J., & Sano, S. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.255 · Cited by 236
Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer
Prasad, S., Phromnoi, K., Yadav, V. R., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Planta Medica · doi:10.1055/s-0030-1250111 · Cited by 231
Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts
Watson, C. J. E., & Miller, W. R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.162 · Cited by 226
STAT3 as a therapeutic target in head and neck cancer
Leeman‐Neill, R. J., Lui, V. W. Y., & Grandis, J. R. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.231 · Cited by 225
Self-citation
Clinical and Correlative Results of SWOG S0354: a Phase II Trial of CNTO328 (siltuximab), a Monoclonal Antibody against Interleukin-6 (IL-6), in Chemotherapy Pre-treated Patients with Castration-Resistant Prostate Cancer (CRPC)
Dorff, T., Goldman, B., Pinski, J., Mack, P., Lara, P., Veldhuizen, P. V., Quinn, D., Vogelzang, N., Thompson, I., & Hussain, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 219
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T
Zhang, X., Guo, A., Yu, J., Possemato, A. P., Chen, Y., Zheng, W., Polakiewicz, R. D., Kinzler, K. W., Vogelstein, B., Velculescu, V. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611665104 · Cited by 214
Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration
Michaud‐Levesque, J., Bousquet-Gagnon, N., & Béliveau, R. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.017 · Cited by 209
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Fizazi, K. S., Bono, J. S. D., Fléchon, A., Heidenreich, A., Voog, É., Davis, N. B., Qi, M., Bandekar, R. R., VERMEULEN, J. T., Cornfeld, M. J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 198
Quercetin, a Flavonoid Phytoestrogen, Ameliorates Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through JAK-STAT Pathway in T Lymphocyte
Muthian, G., & Bright, J. J. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000040925.55682.a5 · Cited by 195
Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling
Cao, H., Tse, A. K., Kwan, H. Y., Yu, H., Cheng, C.-Y., Su, T., Fong, W. F., & Yu, Z. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.008 · Cited by 192
Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice
Zhang, L., Alizadeh, D., Handel, M. M. V., Kortylewski, M., Yu, H., & Badie, B. (2009) · Glia · doi:10.1002/glia.20863 · Cited by 188
An Oxazole-Based Small-Molecule Stat3 Inhibitor Modulates Stat3 Stability and Processing and Induces Antitumor Cell Effects
Siddiquee, K., Gunning, P. T., Glenn, M. P., Katt, W. P., Zhang, S., Schrock, C. E., Sebti, S. M., Jove, R., Hamilton, A. D., & Turkson, J. (2007) · ACS Chemical Biology · doi:10.1021/cb7001973 · Cited by 188
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
Sieper, J., Porter-Brown, B., Thompson, L., Harari, O., & Dougados, M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203559 · Cited by 184
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma
Han, Y., Amin, H. M., Franko, B., Frantz, C., Shi, X., & Lai, R. L. (2006) · Blood · doi:10.1182/blood-2006-04-017434 · Cited by 179
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Tefferi, A. (2012) · Blood · doi:10.1182/blood-2011-11-395228 · Cited by 174
In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy
Xi, S., Gooding, W. E., & Grandis, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1208316 · Cited by 172
Self-citation
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.
木島, 太., Niwa, H., Steinman, R. A., Drenning, S. D., Gooding, W. E., Wentzel, A. L., Xi, S., & Grandis, J. R. (2002) · PubMed · Cited by 164
Self-citation
Inhibition of NK Cell Activity through TGF-β1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer
Dasgupta, S., Bhattacharya‐Chatterjee, M., O’Malley, B. W., & Chatterjee, S. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5541 · Cited by 158
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., Wang, L., Gooding, W. E., Johnson, D. E., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0792 · Cited by 158
Self-citation
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv026 · Cited by 153
Identification of a New Series of STAT3 Inhibitors by Virtual Screening
Matsuno, K., Masuda, Y., Uehara, Y., Satō, H., Muroya, A., Takahashi, O., Yokotagawa, T., Furuya, T., Okawara, T., Otsuka, M., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000273 · Cited by 149
Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways
Takakura, A., Nelson, E. A., Haque, N., Humphreys, B. D., Zandi-Nejad, K., Frank, D. A., & Zhou, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr338 · Cited by 143
Curcumin suppresses constitutive activation of STAT‐3 by up‐regulating protein inhibitor of activated STAT‐3 (PIAS‐3) in ovarian and endometrial cancer cells
Saydmohammed, M., Joseph, D., & Syed, V. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22558 · Cited by 142
Dietary Curcumin Attenuates Glioma Growth in a Syngeneic Mouse Model by Inhibition of the JAK1,2/STAT3 Signaling Pathway
Weissenberger, J., Priester, M., Bernreuther, C., Rakel, S., Glatzel, M., Seifert, V., & Kögel, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0446 · Cited by 142
Interleukin-27 Induces a STAT1/3- and NF-κB-dependent Proinflammatory Cytokine Profile in Human Monocytes
Guzzo, C., Mat, N. F. C., & Gee, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112599 · Cited by 135
Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3
Mandal, P. K., Gao, F., Lü, Z., Ren, Z., Ramesh, R., Birtwistle, J. S., Kaluarachchi, K., Chen, X., Bast, R. C., Liao, W. S. ‐., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000882 · Cited by 130
Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection
Shukla, S., Shishodia, G., Mahata, S., Hedau, S. T., Pandey, A., Bhambhani, S., Batra, S., Basir, S. F., Das, B. C., & Bharti, A. C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-282 · Cited by 124
A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells
Kong, L.-Y., Abou-Ghazal, M. K., Wei, J., Chakraborty, A., Sun, W., Qiao, W., Fuller, G. N., Fokt, I., Grimm, E. A., Schmittling, R. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0377 · Cited by 123
Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Zhang, X., Zhang, J., Wang, L., Wei, H., & Tian, Z. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-149 · Cited by 115
Targeting constitutive and interleukin‐6‐inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane)
Chakravarti, N., Myers, J. N., & Aggarwal, B. B. (2006) · International Journal of Cancer · doi:10.1002/ijc.21967 · Cited by 115
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
Nuclear Factor-κB–Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma
Allen, C. T., Duffy, S. A., Teknos, T. N., Islam, M., Chen, Z., Albert, P. S., Wolf, G. T., & Waes, C. V. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3047 · Cited by 115
Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
Xin, H., Herrmann, A., Reckamp, K. L., Zhang, W., Pal, S. K., Hedvat, M., Zhang, C., Liang, W. P., Scuto, A., Weng, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1217 · Cited by 114
Phase I study of OPB ‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
Ogura, M., Uchida, T., Terui, Y., Hayakawa, F., Kobayashi, Y., Taniwaki, M., Takamatsu, Y., Naoe, T., Tobinai, K., Munakata, W., et al. (2015) · Cancer Science · doi:10.1111/cas.12683 · Cited by 110
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Plimack, E. R., LoRusso, P. M., Mccoon, P. E., Tang, W., Krebs, A. D., Curt, G. A., & Eckhardt, S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0198 · Cited by 110
Quercetin and EGCG Exhibit Chemopreventive Effects in Cholangiocarcinoma Cells via Suppression of JAK/STAT Signaling Pathway
Senggunprai, L., Kukongviriyapan, V., Prawan, A., & Kukongviriyapan, U. (2013) · Phytotherapy Research · doi:10.1002/ptr.5061 · Cited by 108
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
Hayakawa, F., Sugimoto, K., Harada, Y., Hashimoto, N., Ohi, N., Kurahashi, S., & Naoe, T. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.63 · Cited by 108
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes
Leibowitz, M. S., Filho, P. A. A., Ferrone, S., & Ferris, R. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0961-7 · Cited by 105
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer
Lui, V. W. Y., Peyser, N. D., Ng, P. K., Hritz, J., Zeng, Y., Lu, Y., Li, H., Wang, L., Gilbert, B. R., General, I. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319551111 · Cited by 104
Self-citation
Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma
Ashizawa, T., Miyata, H., Iizuka, A., Komiyama, M., Oshita, C., KUME, A., Nogami, M., Yagoto, M., Ito, I., Oishi, T., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1916 · Cited by 101
Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice.
Hayashi, A., Gillen, A. C., & Lott, J. R. (2000) · PubMed · Cited by 98
Hitting the right spot: Mechanism of action of OPB‐31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
Brambilla, L., Genini, D., Laurini, E., Merulla, J., Perez, L. H., Fermeglia, M., Carbone, G. M., Pricl, S., & Catapano, C. V. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.012 · Cited by 98
Quercetin Down-regulates IL-6/STAT-3 Signals to Induce Mitochondrial-mediated Apoptosis in a Nonsmall- cell Lung-cancer Cell Line, A549
Mukherjee, A., & Khuda‐Bukhsh, A. R. (2015) · Journal of pharmacopuncture · doi:10.3831/kpi.2015.18.002 · Cited by 97
The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines
Fossey, S. L., Bear, M. D., Lin, J., Li, C., Schwartz, E. B., Li, P., Fuchs, J. R., Fenger, J. M., Kisseberth, W. C., & London, C. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-112 · Cited by 93
STAT3 tyrosine phosphorylation influences survival in glioblastoma
Birner, P., Tumangelova-Yuzeir, K. D., Natchev, S., & Guentchev, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0195-8 · Cited by 87
TRANSCRIPTION FACTOR STAT3B/DNA COMPLEX
Becker, S., Groner, B., & Müller, C. W. (1998) · Worldwide Protein Data Bank · doi:10.2210/pdb1bg1/pdb · Cited by 82
Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN
Sun, X., Zhang, J., Wang, L., & Tian, Z. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.12.009 · Cited by 80
Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells.
Page, C., Huang, M., Jin, X., Cho, K. R., Lilja, J., Reynolds, R. K., & Lin, J. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.23 · Cited by 80
Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
Burel, S. A., Han, S.-R., Lee, H.-S., Norris, D. A., Lee, B., Machemer, T., Park, S., Zhou, T., He, G., Kim, Y., et al. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0422 · Cited by 77
Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.
Lei, Z., Fan, D., Yi, X., Cao, X., Chen, D., & Wang, L. (2014) · PubMed Central · Cited by 76
Curcumin in clinical practice: myth or reality?
Mancuso, C., & Barone, E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.004 · Cited by 74
Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck
Boehm, A. L., Sen, M., Seethala, R. S., Gooding, W. E., Freilino, M. L., Wong, S. M. Y., Wang, S., Johnson, D. E., & Grandis, J. R. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044636 · Cited by 74
Self-citation
JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth
Sen, M., Pollock, N., Black, J., DeGrave, K. A., Wheeler, S., Freilino, M. L., Joyce, S. C., Lui, V. W. Y., Zeng, Y., Chiosea, S. I., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.01.003 · Cited by 73
Self-citation
Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling
Lu, L., Li, C., Li, D., Wang, Y., Zhou, C., Shao, W., Peng, J., You, Y., Zhang, X., & Shen, X. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1711-x · Cited by 67
NF‐κB and stat3 transcription factor signatures differentiate HPV ‐positive and HPV ‐negative head and neck squamous cell carcinoma
Gaykalova, D. A., Manola, J. B., Ozawa, H., Žižková, V., Morton, K., Bishop, J. A., Sharma, R. B., Zhang, C., Michailidi, C., Considine, M., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29558 · Cited by 65
Inhibition of STAT3 and ErbB2 Suppresses Tumor Growth, Enhances Radiosensitivity, and Induces Mitochondria-Dependent Apoptosis in Glioma Cells
Gao, L., Li, F., Dong, B., Zhang, J., Rao, Y., Cong, Y., Bingzhi, M., & Chen, X. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.036 · Cited by 63
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer
Peyser, N. D., Du, Y., Li, H., Lui, V. W. Y., Xiao, X., Chan, T. A.-T., & Grandis, J. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135750 · Cited by 62
Self-citation
Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells
Gu, J., Li, G., Sun, T., Su, Y., Zhang, X., Shen, J., Tian, Z., & Zhang, J. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9590-9 · Cited by 62
A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance
Haura, E. B., Sommers, E., Song, L., Chiappori, A., & Becker, A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f38f70 · Cited by 58
Integrating Epidermal Growth Factor Receptor Assay With Clinical Parameters Improves Risk Classification for Relapse and Survival in Head-and-Neck Squamous Cell Carcinoma
Chung, C. H., Zhang, Q., Hammond, E. M., Trotti, A., Wang, H., Spencer, S. A., Zhang, H.-Z., Cooper, J. S., Jordan, R. C., Rotman, M., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.024 · Cited by 57
On the Path to Seeking Novel Radiosensitizers
Katz, D., Ito, E., & Liu, F. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.002 · Cited by 56
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer
Peyser, N. D., Freilino, M. L., Wang, L., Zeng, Y., Li, H., Johnson, D. E., & Grandis, J. R. (2015) · Oncogene · doi:10.1038/onc.2015.171 · Cited by 54
Self-citation
A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers
Zhang, M., Xu, C. R., Shamiyeh, E., Liu, F., Yin, J. Y., Moltke, L. L., & Smith, W. B. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.218 · Cited by 53
A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation
Chen, K., Su, J.-C., Liu, C., Huang, J., Chen, K.-C., Chen, W.-L., Tai, W., & Shiau, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.023 · Cited by 50
JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective
Tefferi, A., & Pardanani, A. D. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.06.002 · Cited by 49
Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation
Akiyama (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.957 · Cited by 48
Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Witkiewicz, A. K., Raghunath, P. N., Wasik, A., Junkins‐Hopkins, J. M., Jones, D., Zhang, Q., Ødum, N., & Wasik, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.09.012 · Cited by 47
SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma
Su, J., Tseng, P., Wu, S., Hsu, C.-Y., Tai, W., Li, Y.-S., Chen, I., Liu, C., Chen, K., & Shiau, C. (2014) · Neoplasia · doi:10.1016/j.neo.2014.06.005 · Cited by 46
Sensitization of Head and Neck Cancer to Cisplatin Through the Use of a Novel Curcumin Analog
Abuzeid, W. M., Davis, S. J., Tang, A. L., Saunders, L. M., Brenner, J. C., Lin, J., Fuchs, J. R., Light, E., Bradford, C. R., Prince, M. E., et al. (2011) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archoto.2011.63 · Cited by 44
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray
Kim, H. S., Park, Y. H., Lee, J., Ahn, J., Kim, J., Shim, Y. M., Kim, J. H., Park, K., Han, J., & Ahn, M. (2010) · Cancer · doi:10.1002/cncr.24748 · Cited by 36
A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
Auzenne, E. J., Klostergaard, J., Mandal, P. K., Liao, W. S. ‐., Lü, Z., Gao, F., Bast, R. C., Robertson, F. M., & McMurray, J. S. (2012) · PubMed · Cited by 36
Preclinical Characterization of Signal Transducer and Activator of Transcription 3 Small Molecule Inhibitors for Primary and Metastatic Brain Cancer Therapy
Assi, H. H., Paran, C., VanderVeen, N. T., Savakus, J. C., Doherty, R., Petruzzella, E., Hoeschele, J. D., Appelman, H. D., Raptis, L. H., Mikkelsen, T., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214619 · Cited by 34
The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential
Cutolo, M. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12470753 · Cited by 33
Selfish mothers? An empirical test of parent-offspring conflict over extended parental care
Paul, M., Majumder, S. S., & Bhadra, A. (2013) · Behavioural Processes · doi:10.1016/j.beproc.2013.10.006 · Cited by 30
Attenuation of radiation- and chemoradiation-induced mucositis using gamma-d-glutamyl-l-tryptophan (SCV-07)
Watkins, B. A., Pouliot, K., Fey, E. G., Tuthill, C. W., & Sonis, S. T. (2010) · Oral Diseases · doi:10.1111/j.1601-0825.2010.01671.x · Cited by 30
Immunologic Consequences of Signal Transducers and Activators of Transcription 3 Activation in Human Squamous Cell Carcinoma
Albesiano, E., Davis, M. B., See, A. P., Han, J. E., Lim, M. K., Pardoll, D. M., & Kim, Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4058 · Cited by 25
A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome
Garcia‐Manero, G., Gartenberg, G. J., Steensma, D. P., Schipperus, M. R., Breems, D. A., de Paz, R., Valcárcel, D., Kranenburg, B., Reddy, M. P., & Komrokji, R. S. (2014) · American Journal of Hematology · doi:10.1002/ajh.23780 · Cited by 24
The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain
McMurray, J. S., Mandal, P. K., Liao, W. S. ‐., Klostergaard, J., & Robertson, F. M. (2012) · JAK-STAT · doi:10.4161/jkst.22682 · Cited by 23
Small-molecule STAT3 Signaling Pathway Modulators from Polygonum cuspidatum
Liu, J., Zhang, Q., Chen, K., Liu, J., Kuang, S., Chen, W., & Yu, Q. (2012) · Planta Medica · doi:10.1055/s-0032-1315121 · Cited by 23
Personalized medicine for mucositis: Bayesian networks identify unique gene clusters which predict the response to gamma-d-glutamyl-l-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis
Alterovitz, G., Tuthill, C. W., Rios, I., Modelska, K., & Sonis, S. T. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.07.006 · Cited by 22
2‐Methoxystypandrone inhibits signal transducer and activator of transcription 3 and nuclear factor‐κB signaling by inhibiting Janus kinase 2 and IκB kinase
Kuang, S., Qi, C., Liu, J., Sun, X., Zhang, Q., Sima, Z., Liu, J., Li, W., & Yu, Q. (2014) · Cancer Science · doi:10.1111/cas.12359 · Cited by 22
A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.
Hong, D. S., Younes, A., Fayad, L., Fowler, N. H., Hagemeister, F. B., Mistry, R., Nemunaitis, J. J., Borad, M. J., Bryce, A. H., Yamashita, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8523 · Cited by 17
Dose selection of siltuximab for multicentric Castleman’s disease
Mayer, C. L., Xie, L., Bandekar, R. R., Qi, M., de Velde, H. J. V., Reddy, M. P., Qin, X., Davis, H. M., & Puchalski, T. A. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2720-0 · Cited by 11
JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.
Hurwitz, H. I., Garrett, W. M., Clark, J., Brill, K. J., Dawkins, F. W., Hidalgo, M. M., & Cutsem, E. V. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps4147 · Cited by 7

Sorted by citations

Head and neck squamous cell carcinoma
Johnson, D. E., Burtness, B. A., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00224-3 · Cited by 4,458
Self-citation
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Self-citation
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Oral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 988
Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives
Kumari, A., & Singh, R. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103021 · Cited by 610

See all 193

Authors: Geiger, J. L., Grandis, J. R., & Bauman, J. E.
Affiliations: University of Pittsburgh (US)
University of California, San Francisco (US)
Corresponding author: Bauman, Julie E.
ORCID: Geiger, Jessica L.
Grandis, Jennifer R.
Bauman, Julie E.
Venue: Oral Oncology
Publisher: Elsevier BV
Published: 2016-05
Volume: 56
Pages: 84-92
ISSN: 1368-8375 (ISSN-L)
DOI: 10.1016/j.oraloncology.2015.11.022
PMC: PMC5590227
OpenAlex: W2207542692
Cited by: 193
References: 159
Citations by year: 2026: 11 · 2025: 20 · 2024: 25 · 2023: 13 · 2022: 24 · 2021: 21 · 2020: 25 · 2019: 18 · 2018: 16 · 2017: 15 · 2016: 4
FWCI: 1.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Oral Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (R01CA077308)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: STAT3 signaling, head and neck squamous cell carcinoma, therapeutic target, JAK, epidermal growth factor receptor, treatment resistance, immune evasion, clinical development
MeSH terms: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Humans, Dimerization, STAT3 Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks